Prosecution Insights
Prosecution Insights
Tech Center 4100 • Art Units: 1600 1631 1635 1638 1674 1687 4100 4151
This examiner grants 73% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17261790 | COMPOSITIONS AND METHODS INVOLVING TRANSFORMING EXTRACELLULAR VESICLES | Non-Final OA | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH |
| 18141278 | COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 17687246 | COMPOSITION AND METHODS OF GENOME EDITING OF B-CELLS | Final Rejection | DANA-FARBER CANCER INSTITUTE, INC. |
| 18290257 | PRODUCTION OF ENGINEERED T CELLS FROM STEM CELLS | Non-Final OA | The Regents of the University of California |
| 17777741 | COMPOSITIONS AND METHODS OF USING ENGINEERED FUSION PROTEINS THAT BIND G4C2 HUMAN REPEATS | Final Rejection | The Regents of the University of California |
| 18413096 | RODENTS HAVING A HUMANIZED TMPRSS GENE | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 17775236 | METHODS AND COMPOSITIONS RELATING TO SELECTIVE INTRACELLULAR DELIVERY OF CD38 INHIBITORS | Final Rejection | Ohio State Innovation Foundation |
| 16598833 | COMPOSITION FOR AND METHOD OF FACILITATING CORNEAL TISSUE REPAIR | Non-Final OA | OHIO STATE INNOVATION FOUNDATION |
| 18517703 | ENGINEERED LIGHT-SENSITIVE PROTEINS | Non-Final OA | California Institute of Technology |
| 17767856 | ONCOLYTIC VIRUSES THAT EXPRESS MULTI-SPECIFIC IMMUNE CELL ENGAGERS | Non-Final OA | Arizona Board of Regents on Behalf of Arizona State University |
| 18286923 | MATERIALS AND METHODS FOR NEUROFIBROMIN 2/MERLIN (NF2) GENE THERAPY | Non-Final OA | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 18449940 | DEAD GUIDES FOR CRISPR TRANSCRIPTION FACTORS | Non-Final OA | Massachusetts Institute of Technology |
| 18653847 | ONCOLYTIC VIRUSES AND METHODS OF USE THEREOF FOR THE TREATMENT OF CANCER | Non-Final OA | The Board of Regents of The University of Texas System |
| 18602622 | GENE THERAPY FOR TUBEROUS SCLEROSIS | Non-Final OA | The General Hospital Corporation |
| 18061633 | GENE THERAPY FOR OCULAR DISORDERS | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17904899 | TREATING AUTOSOMAL DOMINANT BESTROPHINOPATHIES AND METHODS FOR EVALUATING SAME | Final Rejection | The Trustees of the University of Pennsylvania |
| 17904903 | TREATING AUTOSOMAL RECESSIVE BESTROPHINOPATHIES AND METHODS FOR EVALUATING SAME | Final Rejection | The Trustees of the University of Pennsylvania |
| 17097997 | COMPOSITIONS FOR DRG-SPECIFIC REDUCTION OF TRANSGENE EXPRESSION | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17046253 | Methods And Compositions Comprising A Viral Vector For Expression Of A Transgene And An Effector | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18340417 | GENOME-EDITED INVARIANT NATURAL KILLER T (INKT) CELLS FOR THE TREATMENT OF HEMATOLOGIC MALIGNANCIES | Non-Final OA | Washington University |
| 18137267 | DEFINED MATRIX FOR THE DIFFERENTIATION OF ISLETS | Final Rejection | Washington University |
| 18282694 | SPONTANEOUS RESPIRATORY BIOMATERIAL FOR TISSUE ENGINEERING | Non-Final OA | IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY) |
| 18009245 | TARGETING OF LACTATE DEHYDROGENASE C, METHODS OF PREPARING SAME, AND METHODS OF USING SAME IN COMBINATION WITH ANTI-CANCER TREATMENTS | Final Rejection | QATAR FOUNDATION FOR EDUCATION, SCIENCE AND COMMUNITY DEVELOPMENT |
| 18595527 | AAV2-MEDIATED GENE DELIVERY OF SFASL AS A NEUROPROTECTIVE THERAPY IN GLAUCOMA | Non-Final OA | Massachusetts Eye and Ear Infirmary |
| 17910459 | DUAL-TARGETING CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS COMPRISING IL-13 AND CHLOROTOXIN FOR CANCER TREATMENT | Non-Final OA | City of Hope |
| 18567470 | Tissue Extracts and Related Methods | Final Rejection | ALLOSOURCE |
| 17783463 | Compositions and Methods of Treating Cancer with Chimeric Antigen Receptors Targeting Glypican 3 | Final Rejection | MEDIMMUNE, LLC |
| 18009320 | CHIMERIC ANTIGEN RECEPTOR CELL | Non-Final OA | UCL Business Ltd |
| 17217612 | Transcription Factor Trapping by RNA in Gene Regulatory Elements | Final Rejection | Whitehead Institute for Biomedical Research |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy